Transcript of Earnings Conference call pertaining to financial results of the Company for the quarter ended June 30, 2026
AI summary
- Q1 FY27 revenue INR384 Cr +20% y-y; EBITDA INR63.5 Cr +10% y-y; PAT INR16.3 Cr +55% y-y
- Base business revenue INR307 Cr +24% y-y; EBITDA INR72 Cr +8% y-y; gross margin ~52-55%
- Ibuprofen business EBITDA margin negative 12%, expected loss INR10-15 Cr per quarter
- Net debt reduced by INR135 Cr (22%) to INR479 Cr; target sub INR450 Cr by Mar-27
- Capex INR55-60 Cr in FY27; focus on debottlenecking capacity with 20-30% volume increase
- Base business capacity utilization ~70%; Vizag facility mothballed pending strategic decisions
- Management cautious on West Asia crisis impact; transparent pricing pass-through ongoing
- Strategic review of ibuprofen business expected by H1 FY27; options being evaluated
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 SOLARA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add SOLARA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Solara Active Pharma Sciences Limited
Important.
The summary above is generated automatically from Solara Active Pharma Sciences Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.